Press releases

Start of clinical research using intermittent NMN infusion

MiraiLabo Bioscience Inc. (Head Office: Chuo-ku, Tokyo; Representative Director: Megumi Tanaka) will provide its NMN infusion as a test drug for the world’s first clinical study using intermittent administration of NMN infusion. This clinical study will be conducted at Tokyo Ginza Wellness & Aging Clinic (Location: Chuo-ku, Tokyo; Director: Takahiro Otani), which is receiving medical support from MEDINET.

Click here to see the press release.

■For inquiries regarding this matter, please contact
MiraiLabo Bioscience Inc.
https://www.mirailab-bio.com/en/contact/

TOP